[{"id":"fd6bc710-bb2e-4704-91c9-a92d773f28a5","acronym":"PALVEN","url":"https://clinicaltrials.gov/study/NCT03900884","created_at":"2021-01-18T19:12:29.046Z","updated_at":"2024-07-02T16:35:01.689Z","phase":"Phase 1","brief_title":"Palbociclib, Letrozole \u0026 Venetoclax in ER and BCL-2 Positive Breast Cancer","source_id_and_acronym":"NCT03900884 - PALVEN","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" HER-2 • ER • BCL2","pipe":" | ","alterations":" ER positive • HER-2 negative • BCL2 positive","tags":["HER-2 • ER • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ibrance (palbociclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 09/25/2019","start_date":" 09/25/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-23"},{"id":"db1b8eee-1daa-4dc5-925d-3727089f2cc4","acronym":"FIL_GAZEBO","url":"https://clinicaltrials.gov/study/NCT05929222","created_at":"2023-07-03T16:10:42.956Z","updated_at":"2024-07-02T16:35:17.926Z","phase":"Phase 3","brief_title":"Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi","source_id_and_acronym":"NCT05929222 - FIL_GAZEBO","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 04/01/2031","primary_completion_date":" 04/01/2031","study_txt":" Completion: 04/01/2031","study_completion_date":" 04/01/2031","last_update_posted":"2024-02-23"},{"id":"bf108067-5ced-452a-b1b7-3bf64d7b834b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05863845","created_at":"2023-05-18T14:04:52.068Z","updated_at":"2024-07-02T16:35:47.684Z","phase":"","brief_title":"Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL","source_id_and_acronym":"NCT05863845","lead_sponsor":"Ruijin Hospital","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • carmustine • melphalan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-05-18"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"f5821b87-a4fd-4f5f-b740-69ab8422f09c","acronym":"FIL_MIRO","url":"https://clinicaltrials.gov/study/NCT02710643","created_at":"2021-01-18T13:15:10.822Z","updated_at":"2024-07-02T16:36:08.555Z","phase":"Phase 2","brief_title":"\"MIRO\" Molecularly Oriented Immuno-radio-therapy","source_id_and_acronym":"NCT02710643 - FIL_MIRO","lead_sponsor":"Fondazione Italiana Linfomi ONLUS","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 04/07/2022","study_completion_date":" 04/07/2022","last_update_posted":"2022-06-21"},{"id":"4adeed15-a02c-4426-90f2-4235120b6f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343536","created_at":"2021-01-18T11:08:23.071Z","updated_at":"2024-07-02T16:36:41.588Z","phase":"Phase 1","brief_title":"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma","source_id_and_acronym":"NCT02343536","lead_sponsor":"Celgene","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 01/29/2020","primary_completion_date":" 01/29/2020","study_txt":" Completion: 01/29/2020","study_completion_date":" 01/29/2020","last_update_posted":"2020-08-28"},{"id":"16e713fe-d4f4-4d99-a9e5-5e68bfd51bf5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560117","created_at":"2021-01-18T06:36:30.171Z","updated_at":"2024-07-02T16:37:14.971Z","phase":"Phase 2","brief_title":"Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma","source_id_and_acronym":"NCT01560117","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 positive • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 07/01/2010","study_completion_date":" 07/01/2010","last_update_posted":"2018-01-09"}]